Searched for
COMBIFLAM ALLEGRA
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...
- Sanofi Consumer Healthcare shares zoom 14% after Q4 profit jumps 50%; declares dividend of Rs 75Sanofi Consumer Healthcare shares surged over 14% following a robust 50% year-on-year net profit increase to Rs 66.5 crore in Q4. Driven by...
- As headwinds slow & managements become realistic, time for a relook: 5 mid-cap pharma stocks with upside potential of up to 44%Every sector goes through a phase when managements become over-optimistic, taking decisions that should have been avoided. But then, with t...
- Mankind may end up spinning out a winner in consumer brands unitThe company entered the OTC business in 2007 and it has grown to have established brands such as Manforce, HealthOK, Prega News, AcneStar, ...
- Sanofi Consumer Healthcare lists on stock exchanges after demerger, shares hit 5% upper circuit on day 1Shares of Sanofi Consumer Healthcare India made their market debut on Friday, listing on both the NSE and BSE. On its first day of trading,...
- Sanofi initiates voluntary recall of Allegra, Combiflam suspensions due to contamination in some batchesSanofi has announced a "temporary halt" on the sales of Allegra Suspension and Combiflam Suspension in India, due to microbiological contam...
- These 5 pharma stocks can give more than 24% returns in one yearCheck out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focu...
- Sanofi plans to launch 1 or 2 products in India every yearSanofi prioritizes the Indian market, focusing on diabetes, consumer health, and innovation. With a strategic shift under Hrosz's leadershi...
- Tactical buys in time of correction? 4 MNC pharma stocks with upside potential of up to 28%In the last two decades MNC pharma companies, whose parent companies were setting up 100 percent owned subsidiaries in India and started ro...
- Will they make a comeback? 4 MNC pharma stocks with upside potential of up to 28%After the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the ...
- Sanofi reinvigorates India business, with eye on higher growthThe company has outlined an ‘India for India’ strategy, where it will focus on diabetes, consumer health, a combination of product innovati...
- Will MNC pharma stocks get back their mojo for good or is it just a blip?Most of the MNC pharma companies have formed their subsidiary and a large majority of new drugs launched in India were via this route. This...
- Sanofi board approves demerger of its consumer healthcare businessThis decision will open new gates for the India business and employees in a value-driven move to accelerate growth for both the pharmaceuti...
- On a path to recovery: 5 midcap pharma stocks with an upside potential up to 32%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized In...
- French drugmaker Sanofi looks to spin off its consumer business in IndiaThe leading vaccine maker is working with Bank of America on the demerger process, said the people cited above. About 60% of Sanofi India i...
- 300 drug formulations to have mandatory bar codes on packages soon to curb sales of spurious medicinesThe decision has been taken in order to curb the sales of spurious medicines. Furthermore, this will also help in checking the authenticity...
- Sanofi's valuations are attractive: Why it is stock pick of weekSanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push...
- Afraid of bears on D-Street? You may just need Vitamin D3The global market for Vitamin D may hit $2.5 billion by 2020 growing at a CAGR of 11 per cent.
- Sanofi India stock likely to be re-rated on company's improving fundamentalsHowever, unlike other multinational pharmaceutical companies, Sanofi India was not analysts’ favourite for quite some time.
Load More
